The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Molecular Partners, a Swiss biotech developing engineered protein therapies for COVID-19 and cancers, raised $64 million by offering 3 million ADSs at $21.25, below the as-converted last close of its shares on the SIX Swiss Exchange ($23.53). Molecular...read more
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
Molecular Partners, a Swiss biotech developing engineered protein therapies for COVID-19 and cancers, announced terms for its IPO on Wednesday. The Zurich, Switzerland-based company plans to raise $81 million by offering 3 million ADSs at $27.14 per share,...read more
US IPO Weekly Recap: IPO market in full swing as biotechs lead a 16 IPO week
The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL)...read more
Swiss biotech Molecular Partners prices US IPO at $21.25
Molecular Partners, a Swiss biotech developing engineered protein therapies for COVID-19 and cancers, raised $64 million by offering 3 million ADSs at $21.25, below the as-converted last close of its shares on the SIX Swiss Exchange ($23.53). Molecular...read more
US IPO Week Ahead: Biotechs and software lead a 15 IPO week
Updated Monday, 6/14. 15 IPOs are currently slated to raise $2.5 billion in the week ahead, led by a preclinical biotech being valued at $4.7 billion. The largest deal of the week, Lyell Immunopharma (LYEL) plans to raise...read more
Swiss biotech Molecular Partners sets terms for $81 million US IPO, targeting COVID-19 and cancer
Molecular Partners, a Swiss biotech developing engineered protein therapies for COVID-19 and cancers, announced terms for its IPO on Wednesday. The Zurich, Switzerland-based company plans to raise $81 million by offering 3 million ADSs at $27.14 per share,...read more